Skip to Main Content

Paper Details

Risk of HLA antibody generation after receipt of Mirasol versus standard platelets in the MIPLATE randomized trial.
Transfusion
1
2023
HLA, HLA antibody, Human, Human leukocyte antigen, Mirasol, Participants, hematological malignancies, immune refractoriness, participants, platelet, standard platelets
Author NameAffiliation
Brian CusterVitalant Research Institute
Brian CusterUniversity of California san francisco
Philip J NorrisUniversity of California san francisco
Philip J NorrisVitalant Research Institute
Philip J NorrisUniversity of California san francisco
  • 1 - 5

Datasets

Release 1.2